Differentiation Therapy and Advances in Cancer

Suzhou, China
October 20-24, 2012

http://www.csh-asia.org/differ12.html

Organizers:
Saijuan Chen, Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong
University School of Medicine, China
Zhu Chen, Ministry of Health P.R. China /Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to
Shanghai Jiao Tong University School of Medicine, China
Samuel Waxman, The Mount Sinai Medical Center, USA

This Cold Spring Harbor conference is merged with the biennial International Conference on Differentiation Therapy (ICDI), which has been recognized as one of the highest-level international scientific meetings in the field of cancer research. Differentiation therapy, which has already shown a targeted, cancer selective therapeutic effect that turned acute promyelocytic leukemia from highly fatal to curable, represents a breakthrough in cancer therapies. This conference is arranged to reflect the most updated advancement in differentiation cancer therapies.

Major Topics:
- Epigenetics and Epigenomics
- Mechanism and impact on cancer therapy
- Genetics and Genomics of Cancer
- Cancer stem cells and novel targets
- Animal models and novel targets
- Targeted Therapies: Present and Future
- Differentiation Therapy of APL and Beyond

Keynote Speakers:
Stephen Baylin, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, USA
Zhu Chen, Ministry of Health P.R. China/Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, China
Carlo Croce, Ohio State University, USA
Samuel Waxman, The Mount Sinai Medical Center, USA

Invited Speakers:
Saijuan Chen, Shanghai Institute of Hematology, Rui-Jin
Hospital affiliated to Shanghai Jiao Tong University School of Medicine, China
John Crispino, Northwestern University, USA
Riccardo Dalla-Favera, Columbia University, USA
Hugues de Thé, Université Paris 7/CNRS, France
Tariq Enver, UCL Cancer Institute, UK
Lorraine Gudas, Weill Cornell Medical College, USA
Zeguang Han, Shanghai Jiaotong University, China
Gunther Hartmann, Universitätsklinikum Bonn, Germany
Scott Hiebert, Vanderbilt University, USA
Shai Izraeli, Sheba Medical Center, Israel
Phillip Koeffler, National University of Singapore, Singapore
Xin Lu, Ludwig Institute For Cancer Research Ltd, UK
Ari Melnick, Weill Cornell Medical College, USA
Tomoki Naoe, Nagoya University Graduate School of Medicine, Japan
Benjamin Neel, Ontario Cancer Institute/MaRs Centre, Canada
Ryuzo Ohno, Aichi Cancer Center Hospital, Japan
Michael Rosenfeld, HHMI/University of California,San Diego, USA
Yongfeng Shang, Tianjin Medical University, China
Yang Shi, Harvard Medical School, USA
Martin Tallman, Memorial Sloan-Kettering Cancer Center,USA
Daniel Tenen, Cancer Science Institute of Singapore, NUS,Singapore
Jun Wang, BIG-Shenzhen, China
Yue Xiong, University of North Carolina at Chapel Hill, USA
Arthur Zelent, Institute of Cancer Research, UK
Yixin Zeng, Peking Union Medical College, China
Qimin Zhan, Peking Union Meidcal College, China